AstraZeneca, in a move to increase its biologics manufacturing capacity in the United States, has acquired a high-tech biologics bulk manufacturing plant in Boulder, Colo., from Amgen Inc.
SUBSCRIBE
Biohealth Innovation
Founding Member of
